Compare Medtronic PLC (MDT) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Nutrien Ltd — how do they compare? Medtronic PLC trades at $82.63 (market cap $106.61B), while Nutrien Ltd trades at $66.8 (market cap $31.67B). The key difference: Medtronic PLC is far larger — about 3.4× Nutrien Ltd's market cap, and Medtronic PLC pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| MDT | NTR | |
|---|---|---|
Market Cap | $106.61B | $31.67B |
Sector | Health | Basic Materials |
52-Week High | $105.35 | $83.94 |
52-Week Low | $73.75 | $53.64 |
Enterprise Value | $125.36B | $44.84B |
Dividend Yield | 3.46% | 3.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $82.35, down 1.02% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS expected at $1.39. Revenue grew to $33.54B in 2025, with a net income margin of 13.2%. Recent news highlights the acquisition of SPR and the launch of AI-powered surgical technology, signaling innovation-driven growth.
The outlook for MDT is positive, supported by analyst consensus with a $97.50 price target and 58% buy ratings. Key opportunities include robust cash flow and dividend stability, while risks involve rising debt levels and competitive pressures in medtech. The stock presents a value proposition with a P/E of 22.33, trading below the consensus target.
Nutrien (NTR) trades at $66.84, down 0.65% with neutral technical signals. The company shows improving fundamentals with Q1 2026 earnings beat and projected revenue growth to $27.8B in 2026. Valuation appears reasonable with P/E of 13.58 and P/S of 1.16. Recent institutional buying activity and a $0.55 dividend payment scheduled for July 2026 provide additional investor appeal.
The outlook remains positive with strong analyst consensus (60.6% buy ratings) and $77.67 price target suggesting 16% upside. Key risks include volatile input costs and fertilizer market dynamics. The combination of reasonable valuation, earnings momentum, and institutional support positions NTR favorably for long-term investors despite near-term market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
